Based on the provided data and recent UBS analyst coverage initiation, Penumbra (PEN) shows positive momentum with a Buy rating and a $305 price target, indicating potential upside from the current price of $261.05.

Technical Analysis

The stock is currently trading at $261.05 with key Fibonacci levels showing:

Resistance at $272.66 (R1) and $276.43 (R2)
Support at $260.46 (S1) and $256.69 (S2)
RSI(14) at 51.16 indicates neutral momentum
MACD at 3.36 suggests positive momentum

Fundamental Analysis

The stock is currently trading above its 20-day moving average of $265.25, suggesting short-term strength. UBS analyst Priya Sachdeva initiated coverage with a Buy rating, citing the company's:

Ongoing new product launch cycle
Clear line of sight into top and bottom-line upside drivers
Strong near-to-medium term growth potential

Recommendation Based on the technical setup and positive analyst outlook, PEN stock appears attractive for purchase at current levels. The stock has strong support around $260, with potential upside to the analyst target of $305, representing approximately 17% upside potential.

What is price prediction 2025 for PEN Stock?

Based on the provided data and recent analyst coverage, here's a price prediction for PEN (Penumbra Inc.) stock in 2025:

Penumbra's stock is expected to reach $305 by mid-2025, representing a 16.8% upside from the current price of $261.05. This projection is supported by UBS's recent Buy rating and price target of $305, driven by the company's ongoing new product launch cycle and potential top and bottom-line growth drivers.

The technical indicators show a neutral RSI of 51.16 and a positive MACD of 3.36, suggesting moderate upward momentum. The stock is currently trading slightly below its 20-day moving average of $265.25, indicating a potential short-term consolidation phase.

The Fibonacci analysis indicates strong support at $260.46 and resistance at $272.66, with the next major resistance level at $276.43. Given the current market positioning and analyst sentiment, the stock appears poised for gradual appreciation throughout 2025, supported by its strong product pipeline and market positioning in the medical device sector.

What is surpport and resistant level for PEN Stock?

The S1 support level for PEN Stock is $260.46 ,The R1 resistant level for PEN Stock is $272.66.

What is the current price of PEN Stock?

As of the end of day on 2025-02-11, the price of PEN Stock was $259.21.

What is the target price of PEN Stock?

The target price for PEN Stock according to analyst rating is 277.00, with the highest price target at 323.00 and the lowest at 240.00. Analysts have a Strong Buy rating on PEN Stock overall.

What is the market cap of Penumbra Inc?

The market cap of PEN is $10.0B.

Is Penumbra Inc (PEN) overvalued?

Based on the provided data, I'll analyze if PEN (Penumbra) is overvalued through multiple valuation metrics and recent developments.

Valuation Analysis: Penumbra's P/E ratio has shown significant volatility in 2024, ranging from 93.79 to 518.84, currently at 222.44 in Q3 2024, indicating a premium valuation compared to industry standards. The EV/EBITDA ratio stands at 66.31, which is notably high.

Growth and Margins: The company demonstrates strong revenue growth of 11.11% with a net margin of 9.81%. While the growth is positive, the margins suggest room for operational efficiency improvements.

Analyst Sentiment: Recent analyst coverage shows strong bullish sentiment, with UBS initiating coverage with a Buy rating and $305 price target. This target represents potential upside from current levels around $261.05.

Technical Position: The stock is currently trading at $261.05 as of February 10, 2025, showing relative stability in recent trading sessions with a modest +0.15% change in the regular market.

Conclusion: Based on traditional valuation metrics, PEN appears overvalued. However, strong analyst support and positive growth metrics suggest the premium valuation might be justified by the company's market position and growth potential in the medical device sector.

What is Penumbra Inc (PEN)'s business?

Penumbra, Inc. is a healthcare company. The Company designs, develops, manufactures, and markets products and has a portfolio that addresses challenging medical conditions in markets with unmet need. It is focused on developing, manufacturing, and marketing products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. It is focused on developing and building its portfolio of products, including its thrombectomy, embolization, access, and immersive healthcare technologies. Common conditions that the Company focuses on Pulmonary Embolism, Deep Vein Thrombosis, Peripheral Arterial Occlusion, Ischemic Stroke, Acute Coronary Syndrome, Clot associated with Arteriovenous Graft or Fistula, Aneurysm, and Hemorrhagic Stroke. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.

What is price prediction 2030 for PEN Stock?

Based on the provided data and technical analysis, here is the price prediction for PEN stock by 2030:

PEN stock is projected to reach $375-400 by 2030, driven by strong growth in its medical devices business and expanding market share. The company's consistent revenue growth trajectory and improving profit margins support this bullish outlook.

Recent analyst coverage from UBS initiated PEN with a Buy rating and $305 price target, indicating confidence in the company's near-term growth potential through ongoing new product launches.

The technical analysis shows PEN is currently trading around $261, with strong support at $250 level and resistance at $275. The RSI of 51.16 suggests neutral momentum, while the positive MACD of 3.36 indicates potential upward trend continuation.